

24 September 2024

## Dr Yujing Lim appointed Executive Director

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to announce that the Board has appointed CEO Dr Yujing Lim as Executive Director, effective immediately.

Dr Lim has been the Chief Executive Officer (CEO) of Osteopore since 18 July 2023, succeeding his appointment as Chief Technology Officer (CTO) in 2018 and Chief Operating Officer (COO) in 2022.

During Dr Lim's term as CEO, has spearheaded an AUD 18.7m partnership with the Agency for Science, Technology and Research (A\*STAR) and the National Dental Centre of Singapore (NDCS), overseen the signing of an exclusive distribution agreement with Top 20 medical device company Zimmer Biomet and secured regulatory access in key regions including ASEAN and the European Union (EU).

Dr Lim is a Doctor of Philosophy (PhD), Bioengineering and Biomedical Engineering graduate from Nanyang Technology University Singapore, and a Master of Engineering (Mechanical Engineering) and Tissue Engineering graduate from the National University of Singapore.

In 2022, Dr Lim was recognised by Pharma Intelligence as one of the 30 people to watch across the biopharma, medtech and healthtech sectors in *In Vivo's Rising Leaders*.

**Commenting on Dr Lim's appointment as Executive Director, Osteopore Executive Chairman Mark Leong, said:**

"Yujing is Osteopore born-and-bred, having dedicated his career to the Company's growth and success. As CEO, he has driven our commercialisation strategy to new heights, achieving record-breaking revenue with six consecutive quarters of growth, all whilst streamlining our cost structure.

"Under his leadership, we've secured key regulatory approvals and successfully launched new applications of our cutting-edge regenerative technology. His strategic insight and unwavering commitment to Osteopore make him a powerful addition to our board, as we continue to push the envelope with regenerative medicine," said Mr Leong.

**ENDS**

This announcement dated 24 September 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

**Mr Mark Leong**

Executive Chairman

Osteopore Limited

E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

**Isaac Stewart**

Media & Investor Relations

Purple

E: [istewart@purple.au](mailto:istewart@purple.au)

**About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

